resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. Strong scientific evidence suggests that aging is regulated by specific biochemical pathways. Medicines that target these biochemical pathways, such as the TORC1 pathway, may prevent or treat a variety of aging related diseases. resTORbioâs lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including immune, neurologic and cardiac function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases. Source
No articles found.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
Catasys has contracted with leading national, regional and local health insurance ...
Catasys has contracted with leading national, r...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Join the National Investor Network and get the latest information with your interests in mind.